Olivier Michielin - ARCHIVE

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


289 publications

Sous presse | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | ...
Sous presse
 
Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K., Mora A.R., van Schaik RHN, Zippelius A., van der Veldt A., Gerard C.L., Läubli H., Michielin O., von Moos R., Joerger M. et al. Journal of immunotherapy. Peer-reviewed.
[DOI][Pmid][serval:BIB_B6930E6F147C]
2024
 
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy.
Taylor A.M., McKeown J., Dimitriou F., Jacques S.K., Zimmer L., Allayous C., Yeoh H.L., Haydon A., Ressler J.M., Galea C. et al., 2024/03. European journal of cancer, 199 p. 113561. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CB58FC4C5C60]
 
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
Jacques S.K., McKeown J., Grover P., Johnson D.B., Zaremba A., Dimitriou F., Weiser R., Farid M., Namikawa K., Sullivan R.J. et al., 2024/03. European journal of cancer, 199 p. 113563. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD78846E78A2]
 
Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23-24, 2023.
Ringborg U., von Braun J., Celis J., Baumann M., Berns A., Eggermont A., Heard E., Heitor M., Chandy M., Chen C.J. et al., 2024/02. Molecular oncology, 18 (2) pp. 245-279. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E812852CFCF3]
 
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Hepner A., Versluis J.M., Wallace R., Allayous C., Brown L.J., Trojaniello C., Gerard C.L., Jansen Y.J., Bhave P., Neyns B. et al., 2024/01. European journal of cancer, 196 p. 113441. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2852520524D8]
2023
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
Anchisi S., Wolfer A., Bisig B., Missiglia E., Tiab A., Kamel E.M., Michielin O., Coukos G., Homicsko K., 2023/12/31. Cancer biology & therapy, 24 (1) p. 2193116. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_365141E36CC9]
 
SwissParam 2023: A Modern Web-Based Tool for Efficient Small Molecule Parametrization.
Bugnon M., Goullieux M., Röhrig U.F., Perez MAS, Daina A., Michielin O., Zoete V., 2023/11/13. Journal of chemical information and modeling, 63 (21) pp. 6469-6475. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BD694B1DEE88]
 
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Mallardo D., Woodford R., Menzies A.M., Zimmer L., Williamson A., Ramelyte E., Dimitriou F., Wicky A., Wallace R., Mallardo M. et al., 2023/10/25. Journal of translational medicine, 21 (1) p. 753. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_79C70FD3661F]
Testing a Model of Care for Patients on Immune Checkpoint Inhibitors Based on Electronic Patient-Reported Outcomes: Protocol for a Randomized Phase II Controlled Trial.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Cuendet M., Muet F., Aedo-Lopez V. et al., 2023/10/18. JMIR research protocols, 12 pp. e48386. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FB6569F97D27]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.
da Silva Lopes A.M., Colomer-Lahiguera S., Darnac C., Giacomini S., Bugeia S., Gutknecht G., Spurrier-Bernard G., Aedo-Lopez V., Mederos N., Latifyan S. et al., 2023/07/22. Supportive care in cancer, 31 (8) p. 484. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EC47A57CA4E0]
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
Schmidt J., Chiffelle J., Perez MAS, Magnin M., Bobisse S., Arnaud M., Genolet R., Cesbron J., Barras D., Navarro Rodrigo B. et al., 2023/06/06. Nature communications, 14 (1) p. 3188. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2898FB2D9415]
 
COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases.
Martin P., Tsourti Z., Ribeiro J., Castelo-Branco L., de Azambuja E., Gennatas S., Rogado J., Sekacheva M., Šušnjar S., Viñal D. et al., 2023/06. ESMO open, 8 (3) p. 101566. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_94155F804FBD]
 
Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
Garbe C., Dummer R., Amaral T., Amaria R.N., Ascierto P.A., Burton E.M., Dreno B., Eggermont AMM, Hauschild A., Hoeller C. et al., 2023/06. Nature medicine, 29 (6) pp. 1310-1312. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_079BED918172]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
 
Single Seminal Vesicle Metastasis From Dorsal Melanoma Detected by 18 F-FDG PET/CT and Confirmed by Biopsy.
Testart Dardel N., Isenborghs E., Valerio M., Michielin O., Schaefer N., 2023/03/01. Clinical nuclear medicine, 48 (3) pp. e151-e152. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E552B0535E6B]
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
Krebs F.S., Moura B., Missiaglia E., Aedo-Lopez V., Michielin O., Tsantoulis P., Bisig B., Trimech M., Zoete V., Homicsko K., 2023/02/24. International journal of molecular sciences, 24 (5) p. 4520. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E3A48A3138B7]
Dendritic cells direct circadian anti-tumour immune responses.
Wang C., Barnoud C., Cenerenti M., Sun M., Caffa I., Kizil B., Bill R., Liu Y., Pick R., Garnier L. et al., 2023/02. Nature, 614 (7946) pp. 136-143. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_33489F389D05]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Interactive process mining of cancer treatment sequences with melanoma real-world data.
Wicky A., Gatta R., Latifyan S., Micheli R., Gerard C., Pradervand S., Michielin O., Cuendet M.A., 2023. Frontiers in oncology, 13 p. 1043683. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DD5F930248D5]
Multilingual RECIST classification of radiology reports using supervised learning.
Mottin L., Goldman J.P., Jäggli C., Achermann R., Gobeill J., Knafou J., Ehrsam J., Wicky A., Gérard C.L., Schwenk T. et al., 2023. Frontiers in digital health, 5 p. 1195017. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6AA8FD72F0E]
2022
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
Gautron Moura B., Gerard C.L., Testart N., Caikovski M., Wicky A., Aedo-Lopez V., Berthod G., Homicsko K., Prior J.O., Dromain C. et al., 2022/12/21. Cancers, 15 (1) p. 31. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0AF72365A8C3]
A differential process mining analysis of COVID-19 management for cancer patients.
Cuendet M.A., Gatta R., Wicky A., Gerard C.L., Dalla-Vale M., Tavazzi E., Michielin G., Delyon J., Ferahta N., Cesbron J. et al., 2022/12/07. Frontiers in oncology, 12 p. 1043675. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_98AD494947E5]
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascenção K., Irving M., Coukos G. et al., 2022/12. Journal of enzyme inhibition and medicinal chemistry, 37 (1) pp. 1773-1811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF494F840FDA]
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C., Keim U., Amaral T., Berking C., Eigentler T.K., Flatz L., Gesierich A., Leiter U., Stadler R., Sunderkötter C. et al., 2022/11/10. Journal of clinical oncology, 40 (32) pp. 3741-3749. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_552F42A6F0C7]
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A., Dettorre G.M., Dafni U., Aguilar-Company J., Castelo-Branco L., Lambertini M., Gennatas S., Angelis V., Sita-Lumsden A., Rogado J. et al., 2022/11. Journal for immunotherapy of cancer, 10 (11) pp. e005732. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43EB088625EB]
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events.
Coukos A., Vionnet J., Obeid M., Bouchaab H., Peters S., Latifyan S., Wicky A., Michielin O., Chtioui H., Moradpour D. et al., 2022/10. Journal for immunotherapy of cancer, 10 (10) pp. e005635. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F836C2B098EA]
Towards a national strategy for digital pathology in Switzerland.
Janowczyk A., Baumhoer D., Dirnhofer S., Grobholz R., Kipar A., de Leval L., Merkler D., Michielin O., Moch H., Perren A. et al., 2022/10. Virchows Archiv, 481 (4) pp. 647-652. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_329EB5DFD086]
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Ascierto P.A., Agarwala S.S., Blank C., Caracò C., Carvajal R.D., Ernstoff M.S., Ferrone S., Fox B.A., Gajewski T.F., Garbe C. et al., 2022/09/04. Journal of translational medicine, 20 (1) p. 391. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4E798A46CDF9]
An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves.
Wysocki O., Zhou C., Rogado J., Huddar P., Shotton R., Tivey A., Albiges L., Angelakas A., Arnold D., Aung T. et al., 2022/08/16. Cancers, 14 (16) p. 3931. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB438C1281CE]
 
Structure-based prediction of BRAF mutation classes using machine-learning approaches.
Krebs F.S., Britschgi C., Pradervand S., Achermann R., Tsantoulis P., Haefliger S., Wicki A., Michielin O., Zoete V., 2022/07/22. Scientific reports, 12 (1) p. 12528. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5CB3AA02B4B8]
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I., Zakria D., Ahmed T., Trojanello C., Dimitriou F., Allayous C., Gerard C., Zimmer L., Lo S., Michielin O. et al., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004610. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D204CE09BBCB]
 
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Bhave P., Ahmed T., Lo S.N., Shoushtari A., Zaremba A., Versluis J.M., Mangana J., Weichenthal M., Si L., Lesimple T. et al., 2022/07. Journal for immunotherapy of cancer, 10 (7) pp. e004668. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B4F52EB38286]
 
Author Correction: Clinical relevance of tumour-associated macrophages.
Pittet M.J., Michielin O., Migliorini D., 2022/06..
[DOI][WoS][Pmid][serval:BIB_60BF1DA61627]
 
Clinical relevance of tumour-associated macrophages.
Pittet M.J., Michielin O., Migliorini D., 2022/06. Nature reviews. Clinical oncology, 19 (6) pp. 402-421. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B8D7D43FF169]
COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE).
Castelo-Branco L., Tsourti Z., Gennatas S., Rogado J., Sekacheva M., Viñal D., Lee R., Croitoru A., Vitorino M., Khallaf S. et al., 2022/06. ESMO open, 7 (3) p. 100499. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_880DB2367FE3]
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Homicsko K., Dummer R., Hoeller C., Wolchok J.D., Hodi F.S., Larkin J., Ascierto P.A., Atkinson V., Robert C., Postow M.A. et al., 2022/05/05. Cancers, 14 (9) p. 2300. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4D579FC357B1]
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
Lee R.J., Wysocki O., Zhou C., Shotton R., Tivey A., Lever L., Woodcock J., Albiges L., Angelakas A., Arnold D. et al., 2022/05. JCO clinical cancer informatics, 6 pp. e2100177. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5BE25E8275C]
Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA).
Joerger M., Metaxas Y., Zaman K., Michielin O., Mach N., Bettini A., Schmitt A.M., Cantoni N., Caspar C.B., Stettler S. et al., 2022/04/27. Cancers, 14 (9) p. 2191. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D0043AF001BA]
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.
Nardou K., Nicolas M., Kuttler F., Cisarova K., Celik E., Quinodoz M., Riggi N., Michielin O., Rivolta C., Turcatti G. et al., 2022/03/19. Cancers, 14 (6) p. 1575. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_878327B7BEC9]
Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors.
Drobni Z.D., Michielin O., Quinaglia T., Zlotoff D.A., Zubiri L., Gilman H.K., Supraja S., Merkely B., Muller V., Sullivan R.J. et al., 2022/03. European journal of cancer, 163 pp. 108-118. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_79B502336559]
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
Aedo-Lopez V., Gérard C.L., Boughdad S., Gautron Moura B., Berthod G., Digklia A., Homicsko K., Schaefer N., Duran R., Cuendet M.A. et al., 2022/02/24. Cancers, 14 (5) p. 1162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F8308EFA619]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
 
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger S.M., Buder-Bakhaya K., Lo S.N., Forschner A., McKean M., Zimmer L., Khoo C., Dummer R., Eroglu Z., Buchbinder E.I. et al., 2022/02. European journal of cancer, 162 pp. 22-33. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC41A790D28F]
The SwissSimilarity 2021 Web Tool: Novel Chemical Libraries and Additional Methods for an Enhanced Ligand-Based Virtual Screening Experience.
Bragina M.E., Daina A., Perez MAS, Michielin O., Zoete V., 2022/01/12. International journal of molecular sciences, 23 (2) p. 811. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9174E37AD078]
SwissBioisostere 2021: updated structural, bioactivity and physicochemical data delivered by a reshaped web interface.
Alessandro C., Antoine D., Marta A S P., Olivier M., Vincent Z., 2022/01/07. Nucleic acids research, 50 (D1) pp. D1382-D1390. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B45F1019EA9E]
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies.
Michielin O., Lalani A.K., Robert C., Sharma P., Peters S., 2022/01. Journal for immunotherapy of cancer, 10 (1) pp. e003024. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EB4E8449258]
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V., Kurt M., Zhang L., Butler M.O., Michielin O., Amadi A., Hernlund E., Johnson H.M., Kotapati S., Moshyk A. et al., 2022. MDM policy & practice, 7 (1) p. 23814683221089659. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0DDC4E311C75]
 
Structural Prediction of Peptide–MHC Binding Modes
Perez Marta A. S., Cuendet Michel A., Röhrig Ute F., Michielin Olivier, Zoete Vincent, 2022. pp. 245-282 dans Computational Peptide Science, Springer US.
[DOI][Pmid][serval:BIB_5B61FB9FCC6D]
2021
Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig U.F., Michielin O., Zoete V., 2021/12/23. Journal of medicinal chemistry, 64 (24) pp. 17690-17705. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_27218E957A69]
 
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation.
Duraiswamy J., Turrini R., Minasyan A., Barras D., Crespo I., Grimm A.J., Casado J., Genolet R., Benedetti F., Wicky A. et al., 2021/12/13. Cancer cell, 39 (12) pp. 1623-1642.e20. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4A546D8AF05A]
 
Turning tumors from cold to inflamed to improve immunotherapy response.
Gerard C.L., Delyon J., Wicky A., Homicsko K., Cuendet M.A., Michielin O., 2021/12. Cancer treatment reviews, 101 p. 102227. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AB33FCA1873]
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D., Degrauwe N., Michielin O., Monney P., Özdemir B.C., 2021/11. Cancer treatment reviews, 100 p. 102282. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_63661F460346]
Patient-reported outcomes for monitoring symptomatic toxicities in cancer patients treated with immune-checkpoint inhibitors: A Delphi study.
Da Silva Lopes A.M., Colomer-Lahiguera S., Mederos Alfonso N., Aedo-Lopez V., Spurrier-Bernard G., Tolstrup L.K., Pappot H., Aspeslagh S., Rogiers A., Neyns B. et al., 2021/11. European journal of cancer, 157 pp. 225-237. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5AEE20D374F]
68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis.
Boughdad S., Latifyan S., Fenwick C., Bouchaab H., Suffiotti M., Moslehi J.J., Salem J.E., Schaefer N., Nicod-Lalonde M., Costes J. et al., 2021/10. Journal for immunotherapy of cancer, 9 (10) pp. e003594. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6D88B7F593BA]
 
Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers M.L., Dimitriou F., Lau P., Bhave P., McArthur G.A., Zimmer L., Kudura K., Gérard C.L., Levesque M.P., Michielin O. et al., 2021/10. European journal of cancer, 156 pp. 149-163. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A82FBE1EAA00]
 
1686P Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study
Lopes A.M.D.S., Colomer-Lahiguera S., Mederos-Alfonso N-N., Lopez V. Aedo, Spurrier-Bernard G., Tolstrup L.K., Pappot H., Aspeslagh S., Rogiers A., Neyns B. et al., 2021/09., ESMO Congress 2021 pp. S1180 dans Annals of Oncology.
[DOI][WoS][serval:BIB_8EB95DA9992D]
Acute cardiac manifestations under immune checkpoint inhibitors-beware of the obvious: a case report.
Arangalage D., Pavon A.G., Özdemir B.C., Michielin O., Schwitter J., Monney P., 2021/08. European heart journal. Case reports, 5 (8) pp. ytab262. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E2AAE474DB65]
 
Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.
da Silva I.P., Ahmed T., Reijers ILM, Warner A.B., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Zimmer L., Trojaniello C. et al., 2021/08. The Lancet. Oncology, 22 (8) pp. e343-e344. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D51407044D20]
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
Thouvenin L., Charrier M., Clement S., Christinat Y., Tille J.C., Frigeri M., Homicsko K., Michielin O., Bodmer A., Chappuis P.O. et al., 2021/08. Gynecologic oncology reports, 37 p. 100787. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AB2F51C1A9EA]
 
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Hepner A., Atkinson V.G., Larkin J., Burrell R.A., Carlino M.S., Johnson D.B., Zimmer L., Tsai K.K., Klein O., Lo S.N. et al., 2021/08. European journal of cancer, 153 pp. 213-222. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1A7F34C37268]
 
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L., Elewaut A., Gerard C.L., Umkehrer C., Leiendecker L., Pedersen M., Krecioch I., Hoffmann D., Novatchkova M., Kuttke M. et al., 2021/07. Nature cancer, 2 (7) pp. 693-708. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_630A38C698EC]
 
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Owen C.N., Bai X., Quah T., Lo S.N., Allayous C., Callaghan S., Martínez-Vila C., Wallace R., Bhave P., Reijers ILM et al., 2021/07. Annals of oncology, 32 (7) pp. 917-925. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4024F0C5F587]
Machine learning analyses of antibody somatic mutations predict immunoglobulin light chain toxicity.
Garofalo M., Piccoli L., Romeo M., Barzago M.M., Ravasio S., Foglierini M., Matkovic M., Sgrignani J., De Gasparo R., Prunotto M. et al., 2021/06/10. Nature communications, 12 (1) p. 3532. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8025CE5AB3D3]
 
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I., Ahmed T., Reijers ILM, Weppler A.M., Betof Warner A., Patrinely J.R., Serra-Bellver P., Allayous C., Mangana J., Nguyen K. et al., 2021/06. The Lancet. Oncology, 22 (6) pp. 836-847. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_001DC1DD3B64]
Cystathionine-gamma-lyase overexpression in T cells enhances antitumor effect independently of cysteine autonomy.
Lancien M., Gueno L., Salle S., Merieau E., Beriou G., Nguyen T.H., Abidi A., Dilek N., Solomon P., Poschmann J. et al., 2021/05. Cancer science, 112 (5) pp. 1723-1734. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_145E54BFE34D]
 
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E., Wicky A., Bouchaab H., Imbimbo M., Delyon J., Gautron Moura B., Gérard C.L., Latifyan S., Özdemir B.C., Caikovski M. et al., 2021/05. European journal of cancer, 149 pp. 153-164. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4791AD7F437D]
 
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
Dimitriou F., Zaremba A., Allayous C., Kähler K.C., Gerard C.L., Festino L., Schäfer S., Toussaint F., Heinzerling L., Hassel J.C. et al., 2021/05. European journal of cancer, 149 pp. 37-48. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDCE3AC07754]
Suivi téléphonique des patients testés positifs au SARS-CoV-2 au Département d’oncologie du CHUV [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]
Jankovic J., Da Silva Lopes A.M., Morez A., Darnac C., Demicheli R., Dalla-Vale M., Lauriers N., Garcia Sanchez J., Bouchaab H., Ninane F. et al., 2021/04/07. Revue medicale suisse, 17 (733) pp. 703-707. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B502B1BCD7F4]
Impact de la pandémie de Covid sur la détection des cancers de la peau [Impact of COVID pandemic on the detection of skin cancer]
Triboulet C., Amblas A., Vernez M., Michielin O., Gaide O., 2021/03/31. Revue medicale suisse, 17 (732) pp. 635-639. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_729DC505DFD7]
 
Probing the Conformational Dynamics of Affinity-Enhanced T Cell Receptor Variants upon Binding the Peptide-Bound Major Histocompatibility Complex by Hydrogen/Deuterium Exchange Mass Spectrometry.
Merkle P.S., Trabjerg E., Hongjian S., Ferber M., Cuendet M.A., Jørgensen TJD, Luescher I., Irving M., Zoete V., Michielin O. et al., 2021/03/23. Biochemistry, 60 (11) pp. 859-872. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF7649E47A67]
Swiss-PO: a new tool to analyze the impact of mutations on protein three-dimensional structures for precision oncology.
Krebs F.S., Zoete V., Trottet M., Pouchon T., Bovigny C., Michielin O., 2021/03/18. NPJ precision oncology, 5 (1) p. 19. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A929D45E3DA0]
 
Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.
Hong A., Piva M., Liu S., Hugo W., Lomeli S.H., Zoete V., Randolph C.E., Yang Z., Wang Y., Lee J.J. et al., 2021/03. Cancer discovery, 11 (3) pp. 714-735. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_642840149803]
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig U.F., Majjigapu S.R., Reynaud A., Pojer F., Dilek N., Reichenbach P., Ascencao K., Irving M., Coukos G., Vogel P. et al., 2021/02/25. Journal of medicinal chemistry, 64 (4) pp. 2205-2227. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FC8F8F2B6EC]
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler J.M., Karasek M., Koch L., Silmbrod R., Mangana J., Latifyan S., Aedo-Lopez V., Kehrer H., Weihsengruber F., Koelblinger P. et al., 2021/02. Journal for immunotherapy of cancer, 9 (2) pp. e001701. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_044C379CA9CC]
2020
 
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
Özdemir B.C., Latifyan S., Perreau M., Fenwick C., Alberio L., Waeber G., Spertini F., de Leval L., Michielin O., Obeid M., 2020/12. Annals of oncology, 31 (12) pp. 1775-1778. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DC85C792AD0C]
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Trama A., Proto C., Whisenant J.G., Torri V., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J., Pancaldi V. et al., 2020/11/09. Cancer cell, 38 (5) pp. 602-604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F92D71268C4]
 
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee.
Michielin O., van Akkooi A., Lorigan P., Ascierto P.A., Dummer R., Robert C., Arance A., Blank C.U., Chiarion Sileni V., Donia M. et al., 2020/11. Annals of oncology, 31 (11) pp. 1449-1461. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80D2F0076B33]
 
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee.
Keilholz U., Ascierto P.A., Dummer R., Robert C., Lorigan P., van Akkooi A., Arance A., Blank C.U., Chiarion Sileni V., Donia M. et al., 2020/11. Annals of oncology, 31 (11) pp. 1435-1448. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B130050026C9]
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology.
Krebs F.S., Gérard C., Wicky A., Aedo-Lopez V., Missiaglia E., Bisig B., Trimech M., Michielin O., Homicsko K., Zoete V., 2020/10/28. International journal of molecular sciences, 21 (21) pp. E8021. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_44F221AEB60A]
Prise en charge par l’ORL des mélanomes cutanés cervico-faciaux [ENT management of head and neck cutaneous melanoma]
Jaballah Vinckenbosch P., Litzistorf Y., Gaide O., Özdemir B.C., Michielin O., Reinhard A., 2020/10/07. Revue medicale suisse, 16 (709) pp. 1853-1859. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_844B37B67CDB]
Evolving impact of long-term survival results on metastatic melanoma treatment.
Michielin O., Atkins M.B., Koon H.B., Dummer R., Ascierto P.A., 2020/10. Journal for immunotherapy of cancer, 8 (2) pp. e000948. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CD4A9414B04C]
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
Curigliano G., Banerjee S., Cervantes A., Garassino M.C., Garrido P., Girard N., Haanen J., Jordan K., Lordick F., Machiels J.P. et al., 2020/10. Annals of oncology, 31 (10) pp. 1320-1335. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_957BAED3FD8F]
What Role Can Process Mining Play in Recurrent Clinical Guidelines Issues? A Position Paper.
Gatta R., Vallati M., Fernandez-Llatas C., Martinez-Millana A., Orini S., Sacchi L., Lenkowicz J., Marcos M., Munoz-Gama J., Cuendet M.A. et al., 2020/09/11. International journal of environmental research and public health, 17 (18) pp. E6616. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F0FD74FBD2EB]
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
Middleton M.R., Hoeller C., Michielin O., Robert C., Caramella C., Öhrling K., Hauschild A., 2020/09. British journal of cancer, 123 (6) pp. 885-897. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ED664BCFFB6F]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C. et al., 2020/07. The Lancet. Oncology, 21 (7) pp. 914-922. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7ACA42FE2BEB]
 
SPHN/PHRT - MedCo in Action: Empowering the Swiss Molecular Tumor Board with Privacy-Preserving and Real-Time Patient Discovery.
Raisaro J.L., Troncoso-Pastoriza J.R., Pradervand S., Cuendet M., Misbach M., Sa J., Marino F., Freundler N., Rosat N., Cavin D. et al., 2020/06/16. Studies in health technology and informatics, 270 pp. 1161-1162. Peer-reviewed.
[DOI][Pmid][serval:BIB_3077196DA0EB]
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant J.G., Trama A., Torri V., De Toma A., Viscardi G., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J. et al., 2020/06/08. Cancer cell, 37 (6) pp. 742-745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F9BFA1700A3B]
Cardiotoxicité des inhibiteurs de points de contrôle immunitaire utilisés dans le traitement des cancers [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment]
Arangalage D., Pavon A.G., Hugelshofer S., Desgraz B., Tzimas G., Delyon J., Muller O., Obeid M., Ribi C., Michielin O. et al., 2020/06/03. Revue medicale suisse, 16 (696) pp. 1165-1168. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A124D4D50BD9]
Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]
Huber A., Latifyan S., Nikolopoulou A., Homicsko K., Berthod G., Michielin O., Özdemir B.C., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1092-1097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E5DDB348D97F]
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
Zimmermann S., Dietrich P.Y., Michielin O., Betticher D., Peters S., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 819-822. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0B2FC89C06E5]
The Great Debate at "Melanoma Bridge", Naples, December 7th, 2019.
Ascierto P.A., Agarwala S.S., Eggermont A., Gershenwald J.E., Grob J.J., Hamid O., Michielin O., Postow M., Puzanov I., Zarour H.M. et al., 2020/04/16. Journal of translational medicine, 18 (1) p. 171. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B856D78550C3]
 
First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver.
Ponti A., Denys A., Digklia A., Schaefer N., Hocquelet A., Knebel J.F., Michielin O., Dromain C., Duran R., 2020/03. Journal of nuclear medicine, 61 (3) pp. 350-356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FD86FE51A57]
Integrating radiomics into holomics for personalised oncology: from algorithms to bedside.
Gatta R., Depeursinge A., Ratib O., Michielin O., Leimgruber A., 2020/02/07. European radiology experimental, 4 (1) p. 11. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_4D7640250026]
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M., Kuncewicz K., Sieradzan A., Karczyńska A., Iwaszkiewicz J., Cesson V., Węgrzyn K., Zhukov I., Maszota-Zieleniak M., Michielin O. et al., 2020/01/18. International journal of molecular sciences, 21 (2). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A28A31EE871C]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][Pmid][serval:BIB_7B31C4DA5F5B]
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
Frisone D., Charrier M., Clement S., Christinat Y., Thouvenin L., Homicsko K., Michielin O., Bodmer A., Chappuis P.O., McKee T.A. et al., 2020. Cancer biology & therapy, 21 (3) pp. 197-202. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DDF548EFECDC]
 
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F., Schiappacasse L., Levivier M., Tuleasca C., Cuendet M.A., Aedo-Lopez V., Gautron Moura B., Homicsko K., Bettini A., Berthod G. et al., 2020/01. Journal of neuro-oncology, 146 (1) pp. 181-193. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_18BD1C202E95]
2019
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V., Dunet V., Hottinger A.F., Berthod G., Schiappacasse L., Peters S., Michielin O., Aedo-Lopez V., 2019/12/02. Journal for immunotherapy of cancer, 7 (1) p. 336. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C48A9CE403D]
 
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
Michielin O., van Akkooi ACJ, Ascierto P.A., Dummer R., Keilholz U., ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, 2019/12/01. Annals of oncology, 30 (12) pp. 1884-1901. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A63CBCEEA279]
 
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.
Dafni U., Michielin O., Lluesma S.M., Tsourti Z., Polydoropoulou V., Karlis D., Besser M.J., Haanen J., Svane I.M., Ohashi P.S. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1902-1913. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DF9E566FB280]
Herpes simplex encephalitis in adult patients with MASP-2 deficiency.
Bibert S., Piret J., Quinodoz M., Collinet E., Zoete V., Michielin O., Menasria R., Meylan P., Bihl T., Erard V. et al., 2019/12. PLoS pathogens, 15 (12) pp. e1008168. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_568322E0BDD0]
 
The Romand Network of Oncology: bridging the gap of personalised oncology
Michielin O., Tsantoulis P., Homicsko K., Christinat Y., De Leval L., Bisig B., Missiaglia E., Zoete V., Krebs F., Fortin A. et al., 2019/10/18. Swiss Medical Weekly.
[serval:BIB_2A3947B3BCE2]
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8DDEE8DA1E]
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
Ascierto P.A., Agarwala S.S., Botti G., Budillon A., Davies M.A., Dummer R., Ernstoff M., Ferrone S., Formenti S., Gajewski T.F. et al., 2019/07/22. Journal of translational medicine, 17 (1) p. 234. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_76EC1D50A2F5]
 
Médecine personnalisée. Bases de la formation interprofessionnelle prégraduée, postgraduée et continue des professionnels de la santé.
Colomer-Lahiguera Sara, 2019/07/08. dans Chapitre 10. La médecine personnalisée en oncologie, Académie Suisse des Sciences Médicales.
[serval:BIB_2F2397E20175]
SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules.
Daina A., Michielin O., Zoete V., 2019/07/02. Nucleic acids research, 47 (W1) pp. W357-W364. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_37625953AF4B]
 
MedCo: Enabling Secure and Privacy-Preserving Exploration of Distributed Clinical and Genomic Data
Raisaro Jean Louis, Troncoso-Pastoriza Juan Ramon, Misbach Mickael, Sousa Joao Sa, Pradervand Sylvain, Missiaglia Edoardo, Michielin Olivier, Ford Bryan, Hubaux Jean-Pierre, 2019/07/01. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 16 (4) pp. 1328-1341. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EB26A9E809D5]
 
Oncologie [Oncology, what's new in 2018]
Latifyan S., Kakourou A., Ozdemir B., Zaman K., Vernadou A., Berthold D., Abdelhamid K., Bouchaab H., Peters S., Montemurro M. et al., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 78-81. Peer-reviewed.
[Pmid][serval:BIB_E686DFA1B1CC]
 
La médecine personnalisée en oncologie dans: Médecine Personnalisée
Colomer-Lahiguera S., Coukos G., Peters S., Kandalaft L., Michielin O., Eicher M., 2019. dans Médecine Personnalisée, Académie Suisse de Sciences Médicales.
[serval:BIB_B2FAEFC8A271]
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
Martins F., Sykiotis G.P., Maillard M., Fraga M., Ribi C., Kuntzer T., Michielin O., Peters S., Coukos G., Spertini F. et al., 2019/01. The Lancet. Oncology, 20 (1) pp. e54-e64. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_42DB9145A8A7]
2018
A severe case of neuro-Sjögren's syndrome induced by pembrolizumab.
Ghosn J., Vicino A., Michielin O., Coukos G., Kuntzer T., Obeid M., 2018/10/22. Journal for immunotherapy of cancer, 6 (1) p. 110. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3E8CC11BAFBA]
CD73 expression and clinical significance in human metastatic melanoma.
Monteiro I., Vigano S., Faouzi M., Treilleux I., Michielin O., Ménétrier-Caux C., Caux C., Romero P., de Leval L., 2018/06/01. Oncotarget, 9 (42) pp. 26659-26669. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_11E2460193C6]
 
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Redelman-Sidi G., Michielin O., Cervera C., Ribi C., Aguado J.M., Fernández-Ruiz M., Manuel O., 2018/06. Clinical microbiology and infection, 24 Suppl 2 pp. S95-S107. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_679ECFFACD23]
 
Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.
Battistello E., Katanayeva N., Dheilly E., Tavernari D., Donaldson M.C., Bonsignore L., Thome M., Christie A.L., Murakami M.A., Michielin O. et al., 2018/05/24. Blood, 131 (21) pp. 2345-2356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_628039C698E5]
 
Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy.
Kudchadkar R.R., Michielin O., van Akkooi ACJ, 2018/05/23. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 38 pp. 759-762. Peer-reviewed.
[DOI][Pmid][serval:BIB_F4007C299F82]
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E8B0234B5672]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer
Tanyi Janos L., Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J., Iseli Christian, Dangaj Denarda et al., 2018/04/11. Science Translational Medicine, 10 (436) pp. eaao5931.
[DOI][WoS][Pmid][serval:BIB_641968BB356B]
 
Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.
Tanyi J.L., Bobisse S., Ophir E., Tuyaerts S., Roberti A., Genolet R., Baumgartner P., Stevenson B.J., Iseli C., Dangaj D. et al., 2018/04/11. Science translational medicine, 10 (436) pp. NA. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CBC10D090AEF]
 
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.
Tétu P., Mangana J., Dummer R., Dutriaux C., Beneton N., Dalle S., Meyer N., Oriano B., Michielin O., Lebbe C., 2018/04. European journal of cancer, 93 pp. 147-149. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4C2D9AD34505]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
Voruz S., Martins F., Cairoli A., Naveiras O., Homicsko K., Missiaglia E., de Leval L., Bisig B., Michielin O., Blum S., 2018/03. Haematologica, 103 (3) pp. e130. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0845E1BF99E5]
ECCO essential requirements for quality cancer care: Melanoma.
Wouters M.W., Michielin O., Bastiaannet E., Beishon M., Catalano O., Del Marmol V., Delgado-Bolton R., Dendale R., Trill M.D., Ferrari A. et al., 2018/02. Critical reviews in oncology/hematology, 122 pp. 164-178. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_51AB46916AFB]
T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.
Bovay A., Zoete V., Dolton G., Bulek A.M., Cole D.K., Rizkallah P.J., Fuller A., Beck K., Michielin O., Speiser D.E. et al., 2018/02. European journal of immunology, 48 (2) pp. 258-272. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_47E01B2BD815]
Lymphatic vessel density is associated with CD8<sup>+</sup> T cell infiltration and immunosuppressive factors in human melanoma.
Bordry N., Broggi MAS, de Jonge K., Schaeuble K., Gannon P.O., Foukas P.G., Danenberg E., Romano E., Baumgaertner P., Fankhauser M. et al., 2018. Oncoimmunology, 7 (8) pp. e1462878. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AD8EABFF0764]
Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma.
Dummer R., Michielin O., Nägeli M.C., M Goldinger S., Campigotto F., Kriemler-Krahn U., Schmid H., Pedroncelli A., Micaletto S., Schadendorf D., 2018. ESMO open, 3 (5) pp. e000388. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_373D1B523FF6]
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
Voruz S., Cairoli A., Naveiras O., de Leval L., Missiaglia E., Homicsko K., Michielin O., Blum S., 2018/01. Haematologica, 103 (1) pp. e39-e41. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_12A8F7D8B626]
2017
Mutant <i>CTNNB1</i> and histological heterogeneity define metabolic subtypes of hepatoblastoma.
Crippa S., Ancey P.B., Vazquez J., Angelino P., Rougemont A.L., Guettier C., Zoete V., Delorenzi M., Michielin O., Meylan E., 2017/11. EMBO molecular medicine, 9 (11) pp. 1589-1604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_ABF970C7CD17]
 
Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
Fankhauser M., Broggi MAS, Potin L., Bordry N., Jeanbart L., Lund A.W., Da Costa E., Hauert S., Rincon-Restrepo M., Tremblay C. et al., 2017/09/13. Science translational medicine, 9 (407) pp. 1-13. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C55698C8F509]
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Mangana J., Cheng P.F., Kaufmann C., Amann V.C., Frauchiger A.L., Stögner V., Held U., von Moos R., Michielin O., Braun R.P. et al., 2017/08. Melanoma research, 27 (4) pp. 358-368. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_15F2678EE65F]
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Dummer R., Hoeller C., Gruter I.P., Michielin O., 2017/06. Cancer immunology, immunotherapy : CII, 66 (6) pp. 683-695. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8B8CACE7B591]
SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules.
Daina A., Michielin O., Zoete V., 2017/03/03. Scientific reports, 7 p. 42717. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8806AF61D608]
A practical guide to the handling and administration of talimogene laherparepvec in Europe.
Harrington K.J., Michielin O., Malvehy J., Pezzani Grüter I., Grove L., Frauchiger A.L., Dummer R., 2017. OncoTargets and therapy, 10 pp. 3867-3880. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_97554E7633A7]
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M., Lach S., Iwaszkiewicz J., Cesson V., Kalejta K., Olive D., Michielin O., Speiser D.E., Zoete V., Derré L. et al., 2017. PloS one, 12 (6) pp. e0179201.
[URN][DOI][WoS][Pmid][serval:BIB_8C02B51C71F2]
 
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Ribas A., Dummer R., Puzanov I., VanderWalde A., Andtbacka RHI, Michielin O., Olszanski A.J., Malvehy J., Cebon J., Fernandez E. et al., 2017. Cell, 170 (6) pp. 1109-1119.e10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A0D6FE5EA58F]
 
The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig U.F., Zoete V., Michielin O., 2017. Biochemistry, 56 (33) pp. 4323-4325. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B02CF9601B42]
 
The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.
Merkle P.S., Irving M., Hongjian S., Ferber M., Jørgensen TJD, Scholten K., Luescher I., Coukos G., Zoete V., Cuendet M.A. et al., 2017. Biochemistry, 56 (30) pp. 3945-3961. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7CF39E44F352]
2016
 
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.-P., Rimoldi D., Gnjatic S. et al., 2016/10/02. OncoImmunology, 5 (10) pp. e1216290.
[DOI][WoS][Pmid][serval:BIB_B9A2EC467477]
 
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.
Murone M., Vaslin Chessex A., Attinger A., Ramachandra R., Shetty S.J., Daginakatte G., Sengupta S., Marappan S., Dhodheri S., Rigotti S. et al., 2016/10. Molecular cancer therapeutics, 15 (10) pp. 2334-2343. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A5C1DEE4954D]
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Dittrich Christian, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas et al., 2016/09. ESMO Open, 1 (5) pp. e000097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FECB702281DB]
Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.
Hoeller C., Michielin O., Ascierto P.A., Szabo Z., Blank C.U., 2016/09. Cancer immunology, immunotherapy : CII, 65 (9) pp. 1015-1034. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_8EBC6CB579E4]
 
SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening.
Zoete V., Daina A., Bovigny C., Michielin O., 2016/08/22. Journal of chemical information and modeling, 56 (8) pp. 1399-1404. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C596B8B7E91E]
Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.
Vallois D., Dobay M.P., Morin R.D., Lemonnier F., Missiaglia E., Juilland M., Iwaszkiewicz J., Fataccioli V., Bisig B., Roberti A. et al., 2016. Blood, 128 (11) pp. 1490-1502. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A7AD3DD77F83]
Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape.
Zoete V., Schuepbach T., Bovigny C., Chaskar P., Daina A., Röhrig U.F., Michielin O., 2016. Journal of Computational Chemistry, 37 (4) pp. 437-447. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2D11A0764FB8]
 
Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.
Golay J., Choblet S., Iwaszkiewicz J., Cérutti P., Ozil A., Loisel S., Pugnière M., Ubiali G., Zoete V., Michielin O. et al., 2016. Journal of Immunology, 196 (7) pp. 3199-3211. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8FAA948539F4]
 
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.
Bonilla X., Parmentier L., King B., Bezrukov F., Kaya G., Zoete V., Seplyarskiy V.B., Sharpe H.J., McKee T., Letourneau A. et al., 2016. Nature Genetics, 48 (4) pp. 398-406. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8EDEF7DDCC06]
 
In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI.
Gonzales C., Yoshihara H.A., Dilek N., Leignadier J., Irving M., Mieville P., Helm L., Michielin O., Schwitter J., 2016. PloS one, 11 (10) pp. e0164557. Peer-reviewed.
[DOI][Pmid][serval:BIB_1C2672B725FA]
 
Principes de la thérapie cellulaire par transfert adoptif à base de Tumor Infiltrating Lymphocytes [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
Martins F., Orcurto A., Michielin O., Coukos G., 2016. Revue Médicale Suisse, 12 (519) pp. 989-993. Peer-reviewed.
[Pmid][serval:BIB_4503E564FA67]
The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.
Dummer R., Siano M., Hunger R.E., Lindenblatt N., Braun R., Michielin O., Mihic-Probst D., von Moos R., Najafi Y., Guckenberger M. et al., 2016. Swiss Medical Weekly, 146 pp. w14279. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1C551DDBD145]
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.P., Rimoldi D., Gnjatic S. et al., 2016. Oncoimmunology, 5 (10) pp. e1216290. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A6A68301DF3E]
Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients - report of a phase I/IIa clinical trial.
Legat A., Maby-El Hajjami H., Baumgaertner P., Cagnon L., Abed Maillard S., Geldhof C., Iancu E.M., Lebon L., Guillaume P., Dojcinovic D. et al., 2016. Clinical Cancer Research, 22 (6) pp. 1330-1340. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9AB3B918AF4A]
2015
 
Immuno-Oncology
Michielin Olivier, Coukos George, 2015/09/09. Progress in Tumor Research, 42, S. Karger AG.
[DOI][serval:BIB_3BABB0481053]
 
Nouvelles immunotherapies du mélanome: mécanismes d'action, efficacité et prise en charge des toxicities [New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities]
Moura B., Homicsko K., Berthod G., Cerottini J.P., Guggisberg D., Gaide O., Maillard M.H., Michielin O., 2015/05/20. Revue medicale suisse, 11 (475) pp. 1108,1110-1114.
[Pmid][serval:BIB_5A4B24BBA8FE]
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
Mangana J., Cheng P.F., Schindler K., Weide B., Held U., Frauchiger A.L., Romano E., Kähler K.C., Rozati S., Rechsteiner M. et al., 2015. Plos One, 10 (10) pp. e0139438. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_468AE65C280D]
 
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
Röhrig U.F., Majjigapu S.R., Vogel P., Zoete V., Michielin O., 2015. Journal of Medicinal Chemistry, 58 (24) pp. 9421-9437. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_97771C01552C]
 
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Michielin O., Hoeller C., 2015. Cancer Treatment Reviews, 41 (8) pp. 660-670. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_11A220401834]
 
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Romano E., Kusio-Kobialka M., Foukas P.G., Baumgaertner P., Meyer C., Ballabeni P., Michielin O., Weide B., Romero P., Speiser D.E., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (19) pp. 6140-6145.
[DOI][WoS][Pmid][serval:BIB_D1CB1536043B]
STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O., De Gassart A., Coso S., Gestermann N., Di Domizio J., Flatz L., Gaide O., Michielin O., Hwu P., Petrova T.V. et al., 2015. Proceedings of the National Academy of Sciences of the United States of America, 112 (50) pp. 15408-15413.
[URN][DOI][WoS][Pmid][serval:BIB_572BDFE9D6A6]
2014
A WXW Motif Is Required for the Anticancer Activity of the TAT-RasGAP317-326 Peptide.
Barras D., Chevalier N., Zoete V., Dempsey R., Lapouge K., Olayioye M.A., Michielin O., Widmann C., 2014. Journal of Biological Chemistry, 289 (34) pp. 23701-23711.
[URN][DOI][WoS][Pmid][serval:BIB_D389856AB093]
 
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., Welters M.J., van der Burg S., Kapiteijn E., Michielin O. et al., 2014. Science Translational Medicine, 6 (254) pp. 254ra128. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_69B53EDF0867]
 
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Röhrig U.F., Majjigapu S.R., Chambon M., Bron S., Pilotte L., Colau D., Van den Eynde B.J., Turcatti G., Vogel P., Zoete V. et al., 2014. European Journal of Medicinal Chemistry, 84 pp. 284-301.
[DOI][WoS][Pmid][serval:BIB_D4D31031A358]
 
Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S., Bouchaab H., Zimmerman S., Bucher M., Gaide O., Letovanec I., Homicsko K., Michielin O., 2014. Melanoma Research, 24 (5) pp. 496-500.
[DOI][WoS][Pmid][serval:BIB_FB42577CAC5A]
 
Ensemble vers l'oncologie de précision [Together, towards precise oncology!].
Coukos G., Michielin O., Dietrich P., Aapro M., 2014. Revue Médicale Suisse, 10 (431) pp. 1099-1100.
[Pmid][serval:BIB_33962F68C3E6]
Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.
Stockinger H., Altenhoff A.M., Arnold K., Bairoch A., Bastian F., Bergmann S., Bougueleret L., Bucher P., Delorenzi M., Lane L. et al., 2014. Nucleic Acids Research, 42 (Web Server issue) pp. W436-W441. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_28A5775B7C38]
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., Speiser D.E., 2014. Cancer Immunology, Immunotherapy : Cii, 63 (3) pp. 247-257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9606B044F312]
 
iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach.
Daina A., Michielin O., Zoete V., 2014. Journal of Chemical Information and Modeling, 54 (12) pp. 3284-3301.
[DOI][WoS][Pmid][serval:BIB_7C3EBBDEAC5D]
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
[URN][DOI][WoS][Pmid][serval:BIB_09C5EADDDF4D]
 
Médecine génomique et oncologie [Genomics medicine and oncology].
Michielin O., Coukos G., 2014. Praxis, 103 (10) pp. 591-596.
[DOI][Pmid][serval:BIB_9B0D168EBA26]
 
Pulmonary Sarcoid-like Granulomatosis after Multiple Vaccinations of a Long-term Surviving Patient with Metastatic Melanoma.
Bordry N., Costa-Nunes C.M., Cagnon L., Gannon P.O., Abed-Maillard S., Baumgaertner P., Murray T., Letovanec I., Lazor R., Bouchaab H. et al., 2014. Cancer Immunology Research, 2 (12) pp. 1148-1153.
[DOI][WoS][Pmid][serval:BIB_3CFC56A8F483]
 
Successes and Limitations of Targeted Cancer Therapy in Melanoma
Peters Solange, Stahel RA (eds.)Romano Emanuela, Michielin Olivier, 2014. Progress in Tumor Research, 41, S. KARGER AG.
[DOI][WoS][Pmid][serval:BIB_CBD38C70CA73]
 
Successes and limitations of targeted cancer therapy in melanoma.
Romano E., Michielin O., 2014. Progress in Tumor Research, 41 pp. 78-88. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC9F2F1C6482]
SwissTargetPrediction: a web server for target prediction of bioactive small molecules.
Gfeller D., Grosdidier A., Wirth M., Daina A., Michielin O., Zoete V., 2014. Nucleic Acids Research, 42 (W1) pp. W32-W38.
[URN][DOI][WoS][Pmid][serval:BIB_4D2B5BC774F4]
 
The caveolin-binding motif of the pathogen-related yeast protein Pry1, a member of the CAP protein superfamily, is required for in vivo export of cholesteryl acetate.
Choudhary V., Darwiche R., Gfeller D., Zoete V., Michielin O., Schneiter R., 2014. Journal of Lipid Research, 55 (5) pp. 883-894. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C1FA8D77E8F]
 
Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R., Goldinger S.M., Turtschi C.P., Eggmann N.B., Michielin O., Mitchell L., Veronese L., Hilfiker P.R., Felderer L., Rinderknecht J.D., 2014. European Journal of Cancer, 50 (3) pp. 611-621. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_69F9A44F4960]
2013
 
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?
Demierre N., Zoete V., Michielin O., Stauffer E., Zimmermann D.R., Betticher D.C., Peters S., 2013. Lung Cancer, 80 (1) pp. 81-84.
[DOI][WoS][Pmid][serval:BIB_5082D60AB0F2]
Axillary Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma Patients after Previous Axillary Surgery: A Systematic Review
Matter M., Romy S., Boubaker A., Michielin O., Demartines N., 2013. Journal of Cancer Therapy, 4 (9) pp. 1395-1402.
[URN][DOI][serval:BIB_A2C5B5C45FA2]
 
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
Peters S., Michielin O., Zimmermann S., 2013. Journal of Clinical Oncology, 31 (20) pp. e341-e344.
[DOI][WoS][Pmid][serval:BIB_0B48F5FB4F2C]
 
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression.
Romano E., Pradervand S., Paillusson A., Weber J., Harshman K., Muehlethaler K., Speiser D., Peters S., Rimoldi D., Michielin O., 2013. Clinical Cancer Research, 19 (20) pp. 5749-5757.
[DOI][WoS][Pmid][serval:BIB_F614E54C2488]
 
Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O., Peters S., Zoete V., Aebersold-Keller F., Strobel K., Schwizer B., Hirschmann A., Michielin O., Diebold J., 2013. Lung Cancer, 82 (2) pp. 365-367.
[DOI][WoS][Pmid][serval:BIB_6113E2F77E4E]
 
Nouvelles armes thérapeutiques contre le mélanome de stade IV [New therapeutic weapons in stage IV melanoma].
Tzika E., Moura B., Romano E., Michielin O., 2013. Revue Médicale Suisse, 9 (387) pp. 1095-1098.
[Pmid][serval:BIB_F68A6EA43ECF]
Persistence of EBV Antigen-Specific CD8 T Cell Clonotypes during Homeostatic Immune Reconstitution in Cancer Patients.
Iancu E.M., Gannon P.O., Laurent J., Gupta B., Romero P., Michielin O., Romano E., Speiser D.E., Rufer N., 2013. Plos One, 8 (10) pp. e78686.
[URN][DOI][WoS][Pmid][serval:BIB_1F8F666B76BA]
Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships.
Fagerberg T., Zoete V., Viatte S., Baumgaertner P., Alves P.M., Romero P., Speiser D.E., Michielin O., 2013. PLoS One, 8 (7) pp. e65590.
[URN][DOI][WoS][Pmid][serval:BIB_D0C48C1C0896]
Protein pocket and ligand shape comparison and its application in virtual screening.
Wirth M., Volkamer A., Zoete V., Rippmann F., Michielin O., Rarey M., Sauer W.H., 2013. Journal of Computer-aided Molecular Design, 27 (6) pp. 511-524.
[URN][DOI][WoS][Pmid][serval:BIB_CEE455C0EFFA]
 
RNA pentaloop structures as effective targets of regulators belonging to the RsmA/CsrA protein family.
Lapouge K., Perozzo R., Iwaszkiewicz J., Bertelli C., Zoete V., Michielin O., Scapozza L., Haas D., 2013. RNA Biology, 10 (6) pp. 1031-1041. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F969FD46661]
Shaping the interaction landscape of bioactive molecules.
Gfeller D., Michielin O., Zoete V., 2013. Bioinformatics, 29 (23) pp. 3073-3079.
[URN][DOI][WoS][Pmid][serval:BIB_8684DDDEADE4]
SHP-1 phosphatase activity counteracts increased T cell receptor affinity.
Hebeisen M., Baitsch L., Presotto D., Baumgaertner P., Romero P., Michielin O., Speiser D.E., Rufer N., 2013. Journal of Clinical Investigation, 123 (3) pp. 1044-1056.
[URN][DOI][WoS][Pmid][serval:BIB_1DC11F4ABA42]
 
Structure-Based, Rational Design of T Cell Receptors.
Zoete V., Irving M., Ferber M., Cuendet M.A., Michielin O., 2013. Frontiers in Immunology, 4 p. 268.
[DOI][WoS][Pmid][serval:BIB_CD515849E397]
SwissBioisostere: a database of molecular replacements for ligand design.
Wirth M., Zoete V., Michielin O., Sauer W.H., 2013. Nucleic Acids Research, 41 (D1) pp. D1137-D1143.
[URN][DOI][WoS][Pmid][serval:BIB_4E944B5211CD]
SwissSidechain: a molecular and structural database of non-natural sidechains.
Gfeller D., Michielin O., Zoete V., 2013. Nucleic Acids Research, 41 (D1) pp. D327-D332. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D528EF3931C]
The Peroxisomal Enzyme L-PBE Is Required to Prevent the Dietary Toxicity of Medium-Chain Fatty Acids.
Ding J., Loizides-Mangold U., Rando G., Zoete V., Michielin O., Reddy J.K., Wahli W., Riezman H., Thorens B., 2013. Cell Reports, 5 (1) pp. 248-258.
[URN][DOI][WoS][Pmid][serval:BIB_32435212F771]
2012
Defining and searching for structural motifs using DeepView/Swiss-PdbViewer.
Johansson M.U., Zoete V., Michielin O., Guex N., 2012. BMC Bioinformatics, 13 p. 173. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AF7C5749A380]
 
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.
Nikolaev S.I., Rimoldi D., Iseli C., Valsesia A., Robyr D., Gehrig C., Harshman K., Guipponi M., Bukach O., Zoete V. et al., 2012. Nature Genetics, 44 (2) pp. 133-139.
[DOI][WoS][Pmid][serval:BIB_6F3F7F30A59D]
 
Expanding molecular modeling and design tools to non-natural sidechains.
Gfeller D., Michielin O., Zoete V., 2012. Journal of Computational Chemistry, 33 (18) pp. 1525-1535.
[DOI][WoS][Pmid][serval:BIB_7B7B0EDE9303]
Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.
Baitsch L., Legat A., Barba L., Fuertes Marraco S.A., Rivals J.P., Baumgaertner P., Christiansen-Jucht C., Bouzourene H., Rimoldi D., Pircher H. et al., 2012. PLoS One, 7 (2) pp. e30852.
[URN][DOI][WoS][Pmid][serval:BIB_3FF2F389E966]
First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R., Seifert B., Simcock M., Goldinger S.M., Gillessen S., Ochsenbein A., Michielin O., Cathomas R., Schläppi M., Moch H. et al., 2012. Annals of Oncology, 23 (2) pp. 531-6.
[URN][DOI][WoS][Pmid][serval:BIB_1D509D2A35CB]
 
Human CD8(+) T cells engineered with supraphysiological TCRs are functionally inhibited via PD-1 and SHP-1 phosphatase
Hebeisen M., Baitsch L., Presotto D., Baumgaertner P., Romero P., Michielin O., Speiser D. E., Rufer N., 2012. p. 713 dans European Congress of Immunology, Immunology.
[WoS][serval:BIB_3E54EE887D6D]
 
Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness.
Irving M., Zoete V., Hebeisen M., Schmid D., Baumgartner P., Guillaume P., Romero P., Speiser D., Luescher I., Rufer N. et al., 2012. Journal of Biological Chemistry, 287 (27) pp. 23068-23078. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_82B9FE6D3127]
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
Goldinger S.M., Dummer R., Baumgaertner P., Mihic-Probst D., Schwarz K., Hammann-Haenni A., Willers J., Geldhof C., Prior J.O., Kündig T.M. et al., 2012. European Journal of Immunology, 42 (11) pp. 3049-3061.
[URN][DOI][WoS][Pmid][serval:BIB_FA34B494C8D3]
 
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07.
Schraml P., von Teichman A., Mihic-Probst D., Simcock M., Ochsenbein A., Dummer R., Michielin O., Seifert B., Schläppi M., Moch H. et al., 2012. Oncology Reports, 28 (2) pp. 654-658.
[DOI][WoS][Pmid][serval:BIB_8159CFCCBBBA]
 
Pulmonary sarcoid-like granulomatosis induced by ipilimumab.
Berthod G., Lazor R., Letovanec I., Romano E., Noirez L., Mazza Stalder J., Speiser D.E., Peters S., Michielin O., 2012. Journal of Clinical Oncology, 30 (17) pp. e156-e159.
[DOI][WoS][Pmid][serval:BIB_2A13971F823C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University